Panobinostat
- Generic Name
- Panobinostat
- Brand Names
- Farydak
- Drug Type
- Small Molecule
- Chemical Formula
- C21H23N3O2
- CAS Number
- 404950-80-7
- Unique Ingredient Identifier
- 9647FM7Y3Z
- Background
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is mar...
- Indication
Panobinostat is indicated in the treatment of multiple myeloma in combination with dexamethasone and bortezomib in patients who have received 2 previous treatment regimens including bortezomib and an immunomodulatory agent. This indication is approved by accelerated approval based on progression free survival as of February 23, 2015.
- Associated Conditions
- Refractory Multiple Myeloma
- Associated Therapies
- -
Panobinostat/Velcade in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 12
- Registration Number
- NCT00891033
- Locations
- 🇺🇸
Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 40
- Registration Number
- NCT00878904
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration
- Conditions
- Interventions
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2018-02-07
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 52
- Registration Number
- NCT00878436
- Locations
- 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸NYU Cancer Center, New York, New York, United States
🇺🇸North Shore University Hospital-Monter Cancer Center, Lake Success, New York, United States
Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
- First Posted Date
- 2009-04-01
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT00873002
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors
- Conditions
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2010-07-16
- Lead Sponsor
- Neurological Surgery, P.C.
- Target Recruit Count
- 6
- Registration Number
- NCT00848523
- Locations
- 🇺🇸
Long Island Brain Tumor Center at Neurological Surgery PC / Long Island Neuro-Oncology Associates, Great Neck, New York, United States
Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 46
- Registration Number
- NCT00840346
- Locations
- 🇪🇸
Hospital Clínico San Carlos. Madrid, Madrid, Spain
🇪🇸Hospital Germans Trías i Pujol, Barcelona, Spain
🇪🇸Hospital Clinic y Provincial de Barcelona, Barcelona, Spain
Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2016-07-15
- Lead Sponsor
- Translational Research in Oncology
- Target Recruit Count
- 54
- Registration Number
- NCT00777049
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT00743288
- Locations
- 🇺🇸
James R. Berenson MD, Incorporated, West Hollywood, California, United States
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Rocky Mountain Cancer Centers - Denver Midtown, Denver, Colorado, United States
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 129
- Registration Number
- NCT00742027
- Locations
- 🇺🇸
University of Pennsylvania Medical Center Dept of UPenn Med Ctr (3), Philadelphia, Pennsylvania, United States
🇺🇸West Virginia University/ Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States
🇺🇸Rush University Medical Center Divisionof Hem/Onc Research(2), Chicago, Illinois, United States
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT00723203
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸South Pasadena Cancer Center, Pasadena, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.